Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinyloestradiol, the estrogen component of Nuvaring, binds to estrogen receptors in the hypothalamus and peripheral tissues. This stabilizes the endometrial lining and, together with the progestin, contributes to suppression of the luteinizing hormone surge, thereby preventing ovulation and creating an environment that is hostile to sperm penetration and implantation.

The dosing regimen for Nuvaring is set by the prescribing healthcare professional. Typically, the ring is inserted into the vagina and left in place for three weeks, followed by a one‑week ring‑free interval during which withdrawal bleeding occurs. Exact instructions, including any adjustments, are individualized based on the patient’s medical history and clinical judgment.

Nuvaring is not intended for use during pregnancy and should be removed immediately if pregnancy is confirmed. While limited data exist for breastfeeding, the product is generally not recommended unless a healthcare provider determines that the benefits outweigh potential risks. Women should discuss alternative contraceptive options with their clinician during pregnancy or lactation.

To order Nuvaring, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both Nuvaring and oral combined contraceptive pills contain estrogen and progestin, but Nuvaring delivers hormones continuously through a vaginal ring, eliminating the need for daily dosing. This can improve adherence and provide more stable hormone levels. Oral pills require daily intake and may have more variable absorption, while the ring offers a three‑week dosing interval followed by a hormone‑free week.

Nuvaring should be stored at room temperature, below 25 °C (77 °F). Keep the ring in its original packaging, protect it from moisture and direct sunlight, and avoid exposing it to extreme temperatures. Do not freeze or refrigerate the product, as temperature fluctuations can affect hormone release and device integrity.

Nuvaring is a flexible vaginal ring that is inserted into the upper vaginal fornix by the user or a healthcare professional. Once placed, it releases a steady dose of hormones for three weeks. After three weeks, the ring is removed, and a one‑week hormone‑free interval follows, during which withdrawal bleeding typically occurs. A new ring is then inserted to continue contraception.

The most serious risks include thromboembolic events such as deep‑vein thrombosis and pulmonary embolism, especially in women with pre‑existing risk factors. Other rare but severe reactions can involve severe allergic responses (anaphylaxis) and liver dysfunction. Patients should be educated to seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe abdominal pain, or signs of an allergic reaction.

Nuvaring is contraindicated in women with a history of venous or arterial thromboembolism, estrogen‑dependent tumors (e.g., certain breast cancers), active or past liver disease, uncontrolled hypertension, or known hypersensitivity to any component of the ring. It is also not recommended for smokers over 35 years of age and should be avoided during pregnancy.